These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33253885)

  • 1. Prediction of plasma profiles of a weakly basic drug after administration of omeprazole using PBPK modeling.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    Eur J Pharm Sci; 2021 Mar; 158():105656. PubMed ID: 33253885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the impact of acid-reducing agents on drug absorption using biorelevant in vitro tools and PBPK modeling - case example dipyridamole.
    Segregur D; Barker R; Mann J; Moir A; Karlsson EM; Turner DB; Arora S; Dressman J
    Eur J Pharm Sci; 2021 May; 160():105750. PubMed ID: 33581261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.
    Shono Y; Jantratid E; Dressman JB
    Eur J Pharm Biopharm; 2011 Oct; 79(2):349-56. PubMed ID: 21527341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biorelevant in vitro Tools and in silico Modeling to Assess pH-Dependent Drug-drug Interactions for Salts of Weak Acids: Case Example Potassium Raltegravir.
    Segregur D; Mann J; Moir A; Karlsson EM; Dressman J
    J Pharm Sci; 2022 Feb; 111(2):517-528. PubMed ID: 34597624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically based pharmacokinetic model outputs depend on dissolution data and their input: Case examples glibenclamide and dipyridamole.
    Klumpp L; Dressman J
    Eur J Pharm Sci; 2020 Aug; 151():105380. PubMed ID: 32442630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study.
    Pawar G; Wu F; Zhao L; Fang L; Burckart GJ; Feng K; Mousa YM; Al Shoyaib A; Jones MC; Batchelor HK
    AAPS J; 2023 Jun; 25(4):67. PubMed ID: 37386339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the oral pharmacokinetic profiles of multiple-unit (pellet) dosage forms using a modeling and simulation approach coupled with biorelevant dissolution testing: case example diclofenac sodium.
    Kambayashi A; Blume H; Dressman JB
    Eur J Pharm Biopharm; 2014 Jul; 87(2):236-43. PubMed ID: 24462791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution behavior of various drugs in different FaSSIF versions.
    Klumpp L; Leigh M; Dressman J
    Eur J Pharm Sci; 2020 Jan; 142():105138. PubMed ID: 31704344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
    Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
    Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2019 Jan; 108(1):584-591. PubMed ID: 30423339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Gastrointestinal Simulator, Mass Transport Analysis, and Absorption Simulation to Investigate the Impact of pH Modifiers in Mitigating Weakly Basic Drugs' Performance Issues Related to Gastric pH: Palbociclib Case Study.
    Kuminek G; Salehi N; Waltz NM; Sperry DC; Greenwood DE; Hate SS; Amidon GE
    Mol Pharm; 2023 Jan; 20(1):147-158. PubMed ID: 36367432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption.
    Kaur N; Narang A; Bansal AK
    Eur J Pharm Biopharm; 2018 Aug; 129():222-246. PubMed ID: 29879527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.